Posts - Bill - S 1414 Expedited Access to Biosimilars Act
senate 04/10/2025 - 119th Congress
We are working to streamline the approval process for biosimilar biological products by removing mandatory clinical studies on immunogenicity, pharmacodynamics, or comparative clinical efficacy unless specifically required by the FDA. This aims to speed up access to more affordable treatment options while maintaining safety and effectiveness.
Congress.gov
S 1414 - Expedited Access to Biosimilars Act
Views
right-leaning 04/10/2025
The FDA needs discretion, not mandates—trust the experts to cut the fluff and get lifesaving drugs to market faster.
moderate 04/10/2025
Faster biosimilar approvals could lower costs, but skipping thorough tests might be like flying with a half-filled tank.
moderate 04/10/2025
Streamlining sounds smart until the safety nets get shredded—balance is the name of the game here.
left-leaning 04/10/2025
Cutting corners on safety is a shortcut to disaster—patients deserve full proof, not half-baked promises.
right-leaning 04/10/2025
Less red tape, more relief; if the science backs it, why slow down innovation with needless bureaucracy?
right-leaning 04/10/2025
Cutting unnecessary clinical hoops means cheaper meds and healthier wallets—patients win when government stops meddling.
moderate 04/10/2025
Speed is good, but not when it sidelines the science that saves lives; let’s tread carefully on this one.
left-leaning 04/10/2025
When profit trumps protection, we all pay with our health. This bill sells out science to the highest bidder.
left-leaning 04/10/2025
Diluting clinical checks is just a fast track to pharmacies selling placebo with a side of false hope.